Thank you, Transcriber B for expanding the transcript. Much appreciated!

Expand full comment

Delighted to find your post. With good wishes, here's a bit more in the way of a partial transcript.

Dr. Ryan Cole On Why (Maybe) Many of the Jabbed Got Lucky

September 17, 2022

Better Way Conference, Austria, first of three videos for that day posted on


(once on the page, scroll on down for the video of the specific day and session. I was unable to get a direct link to the specific video, unfortunately.)


[in answer to a question from a fellow panelist, in essence, why is it that many people do not seem to have had any problem with the shots?]


DR. RYAN COLE: Good manufacturing processes don't exist for this. These are Emergency Authorized Products made in multiple factories around the world at different concentrations. Dr. Burkhardt* and I are in contact with a colleague that has looked at many of these vials. No graphene oxide, just to put that out of your mind. Cholesterol, sugar, salts, and polyethylene glycol in high ratios in some and low in others.

So they're not the same. Each vial from different lots is not the same concentration.

The other thing where a lot of people dodged a bullet and a potential harm is when people lined in stadiums or outside and had these vaccination clinics, these vials weren't kept cold and those vats turned into a glob of mush and the RNA broke down into nothing. So you got a shot of mush. Which— you're lucky. Very lucky. Because it wasn't kept cold.

And so the other thing too is when you stir lipid nanoparticles, polyethylene glycol and mRNA sequences, you can't agitate it quickly. You have to just like put it in a gently slow smooth jazz dance. But when that happens, the lipids kind of float to the top. Now you have thousands of vials going across an assembly line, you know, bup-bup-bup-bup-bup, spitting out the content, and the first couple thousand vials get a very dilute solution, you're not getting a lot of dose of mRNA or lipid. And that would explain our colleagues' findings. But then at the end of that batch now you have some very concentrated lipid mRNA. So in each manufacturing run of this very poor manufacturing process which has lots of debris and lots of vials and all these heebee jeebies and creepy things, are mostly manufacturing debris. And that's again what some of the mass spec we've looked at has shown. You know, it's from stainless steel vats, its from aluminum seals, it's from gaskets, etcetera, it's from crushed glass. You know, all that crazy stuff that's out there, as a pathologist having looked at a lot of these, and there's a big show coming out that you'll see soon, as Dr. Burkhard's colleague has looked at some of these. The more we look at, it's bad manufacturing. And a lot of people—

DR. SUCHARIT BHAKDI: [unaudible]

DR. RYAN COLE: Thank heavens that there's the bad manufacturing. And that answers why a lot of people have been fine. Because if these were— a good manufacturing process in a drug development process takes years, like, 5, 6, 7, 8, 9 years until you have a product pure enough that you can repeat every single time that it comes off the line that it's the same thing. You saw in that early European Medicine Agency last year, 50% pure. It's supposed to be a 99 plus percent pure product. That tells you everything you need to know right there.

But a lot of people are lucky because of that.



# # #


Dr. Cole's webpage is https://www.rcolemd.com/news

and there you can find many of his lectures and interviews.

*Dr. Arne Burkhardt is a retired pathologist. Read the transcript (by another transcriber, I am glad to say) of his talk for the World Council of Heart conference, inaugural Understanding Vaccine Causation Conference, Feb. 5, 2022:


Expand full comment